JP4334761B2 - 肥満の処置 - Google Patents

肥満の処置 Download PDF

Info

Publication number
JP4334761B2
JP4334761B2 JP2000510774A JP2000510774A JP4334761B2 JP 4334761 B2 JP4334761 B2 JP 4334761B2 JP 2000510774 A JP2000510774 A JP 2000510774A JP 2000510774 A JP2000510774 A JP 2000510774A JP 4334761 B2 JP4334761 B2 JP 4334761B2
Authority
JP
Japan
Prior art keywords
peptide
hgh177
animals
treatment
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000510774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002501004A5 (enExample
JP2002501004A (ja
Inventor
フランク・マン−ウーン・ヌグ
ウォエイ−ジア・ジアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Pharmaceuticals Pty Ltd
Original Assignee
Metabolic Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO9001A external-priority patent/AUPO900197A0/en
Priority claimed from AUPP0398A external-priority patent/AUPP039897A0/en
Application filed by Metabolic Pharmaceuticals Pty Ltd filed Critical Metabolic Pharmaceuticals Pty Ltd
Publication of JP2002501004A publication Critical patent/JP2002501004A/ja
Publication of JP2002501004A5 publication Critical patent/JP2002501004A5/ja
Application granted granted Critical
Publication of JP4334761B2 publication Critical patent/JP4334761B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Percussion Or Vibration Massage (AREA)
JP2000510774A 1997-09-08 1998-09-04 肥満の処置 Expired - Fee Related JP4334761B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU0398 1996-06-11
AUPO9001A AUPO900197A0 (en) 1997-09-08 1997-09-08 Treatment of obesity
AUPP0398A AUPP039897A0 (en) 1997-11-13 1997-11-13 Treatment of obesity
AU9001 1997-11-13
PCT/AU1998/000724 WO1999012969A1 (en) 1997-09-08 1998-09-04 Treatment of obesity

Publications (3)

Publication Number Publication Date
JP2002501004A JP2002501004A (ja) 2002-01-15
JP2002501004A5 JP2002501004A5 (enExample) 2005-12-22
JP4334761B2 true JP4334761B2 (ja) 2009-09-30

Family

ID=25645599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510774A Expired - Fee Related JP4334761B2 (ja) 1997-09-08 1998-09-04 肥満の処置

Country Status (12)

Country Link
US (2) US6737407B1 (enExample)
EP (1) EP1012189B1 (enExample)
JP (1) JP4334761B2 (enExample)
CN (1) CN1195776C (enExample)
AT (1) ATE377026T1 (enExample)
BR (1) BR9811755A (enExample)
CA (1) CA2303395C (enExample)
DE (1) DE69838647T2 (enExample)
ES (1) ES2296342T3 (enExample)
NZ (1) NZ502993A (enExample)
RU (1) RU2223970C2 (enExample)
WO (1) WO1999012969A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ387599A0 (en) 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005007859A2 (en) * 2003-07-11 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1755637B8 (en) * 2004-05-04 2012-10-03 Metabolic Pharmaceuticals Ltd. Methods for preventing or treating bone disorders
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
US20110092448A1 (en) * 2005-08-02 2011-04-21 Metabolic Pharmaceuticals Limited Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
WO2008098280A1 (en) * 2007-02-16 2008-08-21 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of dicarba bridges in growth hormone peptides
AU2009292651A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of AOD-like peptides
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
KR102148910B1 (ko) * 2011-12-09 2020-08-28 메타볼릭 파마슈티칼즈 피티와이 엘티디 성장 호르몬 단편들의 사용
CN102827290A (zh) * 2012-09-07 2012-12-19 浙江大学 人血清白蛋白与人生长激素脂肪分解结构域的融合蛋白
GB2507341A (en) * 2012-10-29 2014-04-30 Peter Kenny Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone
WO2019136528A1 (en) * 2018-01-15 2019-07-18 Lateral IP Pty Ltd Peptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG49718A3 (bg) 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US4863901A (en) 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity

Also Published As

Publication number Publication date
DE69838647T2 (de) 2008-08-28
ES2296342T3 (es) 2008-04-16
EP1012189A4 (en) 2004-10-20
EP1012189A1 (en) 2000-06-28
WO1999012969A1 (en) 1999-03-18
RU2223970C2 (ru) 2004-02-20
DE69838647D1 (de) 2007-12-13
US6737407B1 (en) 2004-05-18
NZ502993A (en) 2002-12-20
BR9811755A (pt) 2000-08-29
CN1195776C (zh) 2005-04-06
JP2002501004A (ja) 2002-01-15
ATE377026T1 (de) 2007-11-15
US20040192608A1 (en) 2004-09-30
CN1275132A (zh) 2000-11-29
CA2303395C (en) 2008-12-02
EP1012189B1 (en) 2007-10-31
CA2303395A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
US6737407B1 (en) Treatment of obesity
JP3754072B2 (ja) 摂食抑制ペプチド
EP0828758B1 (en) Chimeric fatty body-pro-grf analogs with increased biological potency
RU2128663C1 (ru) Производные полипептида, обладающие инсулинотропной активностью, фармацевтическая композиция, способы усиления действия инсулина, способы лечения диабета
CN101693736B (zh) 新的肽
CA1341207C (en) Analogues of insulin-like growth factor-1
US6239107B1 (en) Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (VIP)
AU693478B2 (en) Treatment of obesity
AU662731B2 (en) Growth hormone releasing factor analogs
JPH09506873A (ja) 成長ホルモン放出性を有する化合物
CA2083360A1 (en) Tri-arginine insulins
IL98638A (en) Analogs of the factor that releases human growth hormone, their preparation and pharmaceutical preparations that contain them
JPH06502618A (ja) 新規な合成ｇｒｆ類似物
CN108676084B (zh) 艾塞那肽的修饰物及其应用
AU755512B2 (en) Treatment of obesity
JP2004010569A5 (enExample)
KR970001510B1 (ko) 합성 펩타이드 및 이를 포함한 제약학적 조성물
CN117603364A (zh) 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
US6335319B1 (en) Treatment of obesity
CN115819619B (zh) 一类glp-1/y2受体双重激动剂及其应用
AU2007200203A1 (en) Treatment of obesity
JP3733376B2 (ja) ペプチド並びにそれを含有するプロリルエンドペプチダーゼ阻害剤、機能性食品及び動物用飼料
EP1298142A1 (en) Novel gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same
CN118255864A (zh) Gip受体激动剂及其用途
AU5422596A (en) Peptides with growth promotion properties

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080526

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090526

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090624

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120703

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130703

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees